Bovine Parainfluenza Virus 3

Overview and Taxonomy of Bovine Parainfluenza Virus 3

Bovine Parainfluenza Virus 3 (BPIV-3), formally designated as Bovine respirovirus 3 within the family Paramyxoviridae, represents one of the most ubiquitous and economically significant viral pathogens contributing to the bovine respiratory disease complex (BRDC) [1, 3, 4]. Recognizing BPIV-3 not merely as a contributing agent but as a primary viral instigator of respiratory pathology in cattle is fundamental to understanding its profound impact on global livestock health and productivity. This section provides a comprehensive examination of the virus’s taxonomic classification, phylogenetic diversity, genomic organization, and its ecological and epidemiological niche, establishing a foundational framework for the detailed pathogenetic and diagnostic discussions that follow.

Taxonomic Classification and Phylogenetic Position

BPIV-3 is a member of the genus Respirovirus within the subfamily Orthoparamyxovirinae (formerly Paramyxovirinae), family Paramyxoviridae, order Mononegavirales [5, 6, 8]. This taxonomic placement aligns it with other significant respiroviruses, including human parainfluenza virus types 1 and 3 (HPIV-1, HPIV-3) and Sendai virus (murine PIV-1) [15, 16]. The close antigenic and genetic relationship between BPIV-3 and HPIV-3 is particularly noteworthy; indeed, chimeric bovine/human PIV-3 (B/HPIV-3) vectors have been successfully developed and evaluated in clinical trials for pediatric immunization against HPIV-3 and, more recently, as a vector for SARS-CoV-2 vaccines [14]. This cross-species compatibility underscores the shared evolutionary lineage and functional homology between the bovine and human respiroviruses, a feature that has been exploited for vaccine development and basic virological research.

Phylogenetic analyses of BPIV-3 have delineated three distinct genotypes: A, B, and C [7, 13, 21]. The initial characterization of BPIV-3 in the mid-20th century identified the prototype genotype A (BPIV-3a) [8]. For decades, this was considered the predominant circulating type. However, the advent of molecular epidemiological tools has revealed the existence and widespread distribution of genotypes B and C, significantly complicating the genetic landscape of BPIV-3 and providing critical insights into its global evolution. Genotype B was initially identified in Australia and has since been detected in other regions [13]. Genotype C (BPIV-3c), in particular, has emerged as a globally dominant lineage, with reports documenting its circulation in North America, Europe, Asia (including Turkey and China), and South America [7, 13, 18, 21]. The genetic divergence among these genotypes is primarily based on sequence analysis of the nucleocapsid (N), fusion (F), and hemagglutinin-neuraminidase (HN) genes, which encode the major antigenic and structural proteins [13]. The existence of multiple genotypes has profound implications for vaccine efficacy and diagnostic assay design, as cross-protection and detection capabilities may be variable.

Genomic Organization and Molecular Architecture

The BPIV-3 genome consists of a single-stranded, negative-sense RNA molecule approximately 15,480 to 15,520 nucleotides in length [13]. The genome follows the canonical paramyxovirus gene order: 3′-N-P/V/C-M-F-HN-L-5′, encoding six structural proteins in a conserved arrangement. The nucleocapsid (N) protein encapsulates the genomic RNA, forming the helical ribonucleoprotein (RNP) complex that serves as the template for transcription and replication. The phosphoprotein (P) is a crucial cofactor for the viral RNA-dependent RNA polymerase (L protein). The matrix (M) protein orchestrates viral assembly and budding. The fusion (F) and hemagglutinin-neuraminidase (HN) glycoproteins are embedded in the viral envelope and are critical for host cell attachment and entry; HN binds to sialic acid receptors, while F mediates pH-dependent or independent membrane fusion [11, 12]. The large (L) protein functions as the core of the RNA polymerase.

A defining and unique feature of the BPIV-3 genome is the P gene, which employs a sophisticated co-transcriptional RNA editing mechanism to express multiple proteins from a single gene. As demonstrated by Pelet et al. (1991), the P gene contains a single editing site that allows the viral polymerase to insert non-templated guanine (G) residues into the nascent mRNA [9]. This process is remarkably permissive, with a broad distribution of G insertions (e.g., one, two, or three Gs) occurring during transcription. Insertions at this site shift the translational reading frame, allowing access to downstream overlapping open reading frames (ORFs) encoding the V and D proteins. Thus, a single P gene can express all three reading frames as protein products [9]. This editing mechanism is distinct from the more restricted editing seen in other paramyxoviruses like Sendai virus and has critical implications for viral replication, pathogenesis, and immune evasion. The V protein, in particular, is a well-characterized interferon antagonist that is essential for virulence in many paramyxoviruses. This sophisticated genomic structure underscores the evolutionary complexity of BPIV-3 and its capacity to modulate host cellular machinery.

Host Range, Ecology, and Epidemiological Significance

BPIV-3 is a pathogen of primary veterinary importance, with a primary host range that includes domestic cattle (Bos taurus) and water buffalo (Bubalus bubalis) [5, 6, 18]. However, its ecological footprint extends far beyond these species. Serological and virological evidence has confirmed infection in a wide range of domestic and wild ruminants, including sheep, goats, camels, and wood bison (Bison bison athabascae) [10, 21, 30]. A study in Iraq detected BPIV-3 RNA in camels with respiratory illness, demonstrating its ability to infect non-ruminant ungulates [10]. Similarly, reintroduced wood bison in Canada showed an 87% seroprevalence to BPIV-3, indicating widespread exposure in wildlife populations [30]. This broad host range establishes BPIV-3 not just as a disease of cattle but as a multi-species respiratory pathogen capable of circulating within complex ecological networks. The implications for cross-species transmission and the potential for wildlife reservoirs to sustain viral circulation in domestic herds are significant, particularly in regions where cattle share pasture with wildlife or multi-species livestock operations.

The global distribution of BPIV-3 is nearly universal, as evidenced by decades of serological surveys across six continents. Seroprevalence in unvaccinated adult cattle populations frequently exceeds 80% [3, 4, 24]. In Brazil, 96.8% of unvaccinated dairy cows from high-yielding herds were seropositive for BPIV-3 [24]. In Colombia, an 85.9% seroprevalence was reported in cattle from Villavicencio [3]. A comprehensive study in Serbia found animal-level true seroprevalence of 84.59% for BPIV-3, and the virus was present on 100% of surveyed farms [4]. In Turkey, seropositivity rates in cattle ranged from 43% in north-western regions to 56.2% in a recent multi-region study [21, 27]. In Sweden, 48% of calves were seropositive by approximately 7 months of age [22]. Similarly, Norwegian dairy calves had a 50.2% seroprevalence by 150 days of age [29]. In Finland, PIV-3, along with bovine adenoviruses, was identified as a common respiratory pathogen [26]. These data collectively illustrate that BPIV-3 is a hyper-endemic pathogen of young stock worldwide. The infection typically occurs early in life, often in the first few months after weaning or grouping, when maternal antibody wanes and exposure intensity increases.

Environmental and management factors are potent drivers of BPIV-3 transmission and disease manifestation. A robust risk-factor analysis by Küçük et al. (2025) identified that animal transport, housing type, ventilation quality, and the duration from infection onset to sampling were significant univariate risk factors for BPIV-3 detection in Turkish herds [2]. Multivariate analysis further revealed that age, time from infection onset to sampling, and air quality were critical determinants [2]. These findings are corroborated by the World Organisation for Animal Health (WOAH) guidelines on BRDC management, which emphasize that environmental stressors such as overcrowding, poor ventilation, and abrupt changes in diet or climate are critical co-factors that precipitate clinical disease from subclinical infection. In a study of beef steers shipped from France to Italy, the number of animals shedding BPIV-3 increased dramatically after transport, highlighting the role of stress in reactivating or amplifying viral shedding [19]. The virus is shed primarily in nasal secretions, and transmission occurs via direct contact or aerosolized droplets over short distances [17]. The ability of the virus to persist in chronic infections, as demonstrated by Mehinagic et al. (2019) in Swiss cattle co-infected with Mycoplasma bovis, suggests that latent or low-grade viral carriage may play a role in within-herd maintenance and the development of chronic bronchopneumonia [6]. Notably, BPIV-3 has also been detected in aborted bovine fetuses, with evidence of necrotizing bronchiolitis and interstitial pneumonia, indicating that the virus can cross the placenta and cause direct fetal pathology [8, 20]. This reproductive involvement, while less common, adds another layer of complexity to its pathogenesis, with potential economic consequences for breeding operations.

Genetic Diversity and Evolutionary Dynamics

The three genotypes of BPIV-3 (A, B, and C) are distinguished by nucleotide and amino acid differences in key antigenic sites. Whole-genome sequencing and phylogenetic analyses of Chinese isolates have revealed that genotype B (isolate XJ21032-1, 15,512 bp) and genotype C (isolate XJ20055-3, 15,479 bp) possess multiple amino acid changes in the N, F, and HN proteins compared to genotype A [13]. These changes are not silent; they have the potential to alter antigenic epitopes and receptor-binding properties. Indeed, serological surveys comparing neutralization titers against BPIV-3a and BPIV-3c in Turkish domestic ruminants found that the seropositivity rate for genotype C was significantly higher (34.3%) than for genotype A (24.3%) [21]. This differential seroprevalence suggests either that genotype C is more transmissible, induces a stronger antibody response, or is more frequently encountered in the field. It raises a critical question for vaccine strategy: most current commercial modified-live and inactivated vaccines are based on genotype A strains [23]. If genotype C is antigenically distinct, vaccine-induced immunity may be suboptimal against circulating field strains. This issue of antigenic mismatch is a pressing concern for the global cattle industry and demands ongoing molecular surveillance and potential vaccine strain updates.

The epidemiology of BPIV-3 is further complicated by its frequent role in polymicrobial infections. In field studies, BPIV-3 is rarely detected in isolation. In Serbian cattle with clinical BRDC, BPIV-3 was detected by PCR in 10.9% of nasal swabs, but it was frequently found alongside BRSV (20%), BVDV (8%), and bacterial pathogens [4]. In an abattoir study in Egypt, co-infections of BPIV-3 with BVDV were documented in 8.1% of pneumonic lungs, and triple infections with BVDV and BRSV occurred in 1% of cases [25]. In Swiss cattle, BPIV-3 was the predominant agent in chronic pneumonia, persisting in 39 of 104 cases as a single infection and in 39 cases as a co-infection with M. bovis [6]. These data support the WOAH and FAO conceptualization of BPIV-3 as a primary viral initiator of BRDC. The virus damages the respiratory epithelium and suppresses local immune defenses, creating a permissive environment for secondary bacterial colonization by pathogens such as Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni [19, 28]. The intricate interplay between BPIV-3, host immune status, and the microbiome of the respiratory tract is a central theme in the pathogenesis of BRDC and will be explored in subsequent sections.

In summary, BPIV-3 is a globally endemic, genetically diverse member of the Respirovirus genus that infects a wide range of ungulate hosts. Its ability to persist in populations, escape immunity through genetic drift (genotype diversity), and orchestrate polymicrobial infections makes it a linchpin of the BRDC. Understanding its taxonomy and evolutionary dynamics is not an academic exercise but a prerequisite for designing effective diagnostic assays, formulating relevant vaccines, and predicting the ecological drivers of disease outbreaks. The subsequent analysis of its molecular mechanisms of entry, replication, and host-pathogen interaction will build directly upon this foundational overview.

Molecular Pathogenesis and Host-Virus Interactions

The molecular pathogenesis of Bovine Parainfluenza Virus 3 (BPIV-3) is a multifaceted process governed by a complex interplay between viral determinants and host cellular machinery. As a member of the Paramyxoviridae family, genus Respirovirus, BPIV-3 employs a sophisticated arsenal of strategies to invade host cells, subvert innate immune defenses, and establish productive infection. The virus’s ability to cause significant respiratory disease, particularly within the bovine respiratory disease complex (BRDC), is predicated on its capacity to manipulate host signaling pathways, exploit specific entry receptors, and evade interferon-mediated antiviral responses. Understanding these molecular interactions at a granular level is critical for the rational design of antiviral therapeutics and effective vaccines, especially given the virus’s global economic impact on cattle production, a concern recognized by the World Organisation for Animal Health (WOAH).

Viral Entry Mechanisms: A Multi-Pathway, Receptor-Dependent Process

The initial step of BPIV-3 infection, viral entry into susceptible host cells, is a highly orchestrated event that is both cell-type and genotype dependent. The virus initiates infection by binding to sialic acid receptors on the cell surface via its hemagglutinin-neuraminidase (HN) glycoprotein. However, sialic acids alone are incapable of transducing intracellular signals, necessitating the involvement of additional co-receptors to facilitate internalization. Recent evidence has identified the epidermal growth factor receptor (EGFR) as a critical host-entry cofactor for BPIV-3 in Madin-Darby bovine kidney (MDBK) cells [31]. Upon viral attachment, EGFR is activated, leading to downstream signaling cascades that are essential for viral uptake. Specifically, BPIV-3 infection triggers the PI3K-Akt and ERK1/2 pathways in an EGFR-dependent manner, and pharmacological inhibition of these effectors significantly reduces viral entry [31]. Furthermore, the small GTPases Rac1 and Pak1, which are master regulators of actin cytoskeleton remodeling, have been identified as downstream mediators of EGFR signaling during BPIV-3 internalization [31]. This indicates that BPIV-3 hijacks a growth factor receptor signaling axis to orchestrate the cytoskeletal rearrangements necessary for its own engulfment.

The internalization process itself is remarkably versatile, utilizing both clathrin-mediated endocytosis (CME) and macropinocytosis, with the dominant pathway being influenced by the host cell type. In HeLa cells, BPIV-3 entry is strictly dependent on CME, requiring cholesterol, dynamin, and clathrin heavy chain, while being independent of caveolae and macropinocytosis [11]. In contrast, in the physiologically relevant MDBK cell line, BPIV-3 employs a dual-entry strategy, utilizing both CME and macropinocytosis [12]. This cell-type-specific plasticity suggests that the virus can adapt its entry strategy based on the available host machinery. Notably, in MDBK cells, macropinocytosis, but not CME, is dependent on actin dynamics, further highlighting the role of EGFR-mediated cytoskeletal remodeling in this specific pathway [12]. Following internalization, the virus is trafficked to endosomal compartments where a low pH environment is required for fusion. However, the requirement for acidification is not universal; while BPIV-3 entry into MDBK cells is acid-dependent and requires cathepsin L activity, entry into HeLa cells requires endosomal cathepsins but is independent of low pH [11, 12]. This suggests that the proteolytic activation of the fusion (F) protein may be mediated by different host proteases in different cellular contexts.

A genome-scale CRISPR screen has recently provided a comprehensive, unbiased view of the host factors essential for BPIV-3 replication, validating and expanding upon these entry mechanisms [1]. This study identified three key genes required for BPIV-3a replication: WNT5A, SLC16A13, and SELENON. Functional dissection revealed that these genes play distinct roles in the early stages of infection. WNT5A was found to be involved in both viral adhesion and internalization, suggesting a role in the initial attachment or post-attachment signaling events [1]. SLC16A13, a solute carrier family member, was specifically required for internalization but not adhesion, implicating it in the endocytic process itself [1]. Interestingly, SELENON, a selenoprotein involved in redox homeostasis and calcium regulation, had no significant impact on either adhesion or internalization, indicating that its essential function lies in a post-entry step, such as viral RNA replication or assembly [1]. The identification of WNT5A is particularly intriguing, as it is a ligand in the non-canonical Wnt signaling pathway, which is known to regulate cell polarity and cytoskeletal dynamics. This finding further supports the model that BPIV-3 co-opts signaling pathways that control actin remodeling to facilitate its entry.

Evasion of Innate Immunity: The Interferon Antagonism and ISG Countermeasures

A hallmark of paramyxovirus pathogenesis is the ability to subvert the host type I interferon (IFN) response. BPIV-3 is no exception, and its P gene is a central hub for this immune evasion. The P gene of BPIV-3 is unique among paramyxoviruses in that it expresses all three reading frames from a single mRNA editing site [9]. Through a process of co-transcriptional insertion of non-templated G residues, the virus generates a spectrum of mRNAs that encode the P, V, and D proteins [9]. The V protein is a well-characterized interferon antagonist in many paramyxoviruses, and its expression from a single editing site in BPIV-3 underscores its importance. The V protein functions by targeting key components of the IFN induction and signaling pathways, such as STAT proteins and MDA5, thereby dampening the host's antiviral state.

Despite these evasion strategies, the host cell mounts a counterattack through the expression of interferon-stimulated genes (ISGs). One of the most potent ISGs is Viperin (virus inhibitory protein, endoplasmic reticulum-associated, interferon-inducible). Studies have demonstrated that both bovine and caprine Viperin significantly inhibit BPIV-3 and the closely related caprine parainfluenza virus 3 (CPIV3) replication [33]. The antiviral mechanism of Viperin involves a direct physical interaction with the viral nucleocapsid (N) protein [33]. Co-immunoprecipitation and confocal microscopy studies confirmed that Viperin co-localizes and binds specifically to the N protein, but not to the P, C, or V proteins [33]. This interaction likely sequesters the N protein or prevents its proper oligomerization, thereby inhibiting viral RNA synthesis and replication. The C-terminal region of Viperin was identified as the critical domain for this anti-CPIV3 activity [33]. This highlights a specific molecular arms race: the virus uses its V protein to suppress IFN production, while the host deploys Viperin to directly target a core viral structural protein.

The efficacy of exogenous type I IFNs as a prophylactic measure has also been explored. Transcriptomic analysis revealed that CPIV3 infection actively inhibits the production of endogenous type I IFNs, a classic viral immune evasion tactic [32]. However, prophylactic treatment with recombinant goat IFN-α or IFN-τ effectively induced a broad panel of ISGs and established a robust antiviral state that could protect MDBK cells from subsequent BPIV3 and CPIV3 challenge [32]. This protective effect was long-lasting, persisting for up to one week, and was effective at low concentrations [32]. Importantly, the therapeutic application of IFN (given post-infection) was ineffective, underscoring the virus's ability to rapidly establish a replication complex that is refractory to the antiviral effects of IFN once infection is underway [32]. This temporal dynamic is crucial for understanding the window of opportunity for IFN-based therapies.

Host Factors and Viral Replication: Beyond Entry

The molecular pathogenesis of BPIV-3 extends beyond entry and innate immune evasion to include the exploitation of specific host factors for genome replication and virion assembly. The CRISPR screen that identified WNT5A, SLC16A13, and SELENON also demonstrated that these factors are not only essential for BPIV-3a but also for the BPIV-3c genotype and even a different virus, Bovine enterovirus [1]. This suggests that these host factors may be part of a common, essential pathway required by multiple RNA viruses, making them attractive targets for broad-spectrum antiviral development. The fact that SELENON is required for a post-entry step is particularly noteworthy. SELENON is a selenoprotein localized to the endoplasmic reticulum (ER) and is involved in calcium homeostasis and redox sensing. Its requirement for BPIV-3 replication suggests that the virus may rely on the ER's calcium stores or redox environment for proper folding of viral glycoproteins or for the formation of viral replication complexes. The disruption of calcium homeostasis is a known feature of many viral infections, and BPIV-3 may be actively manipulating this pathway.

Furthermore, the viral fusion (F) and hemagglutinin-neuraminidase (HN) proteins are major antigenic determinants and are subject to genetic variation between genotypes. Phylogenetic analyses of BPIV-3 isolates from China have identified multiple amino acid changes in the N, F, and HN proteins between genotype B and C strains [13]. These changes can have profound implications for viral pathogenesis, as they may alter receptor binding specificity, fusion kinetics, or susceptibility to neutralizing antibodies. For instance, the HN protein's balance between hemagglutinin and neuraminidase activities is critical for viral entry and release. Mutations that shift this balance can affect viral fitness and tissue tropism. The emergence of genotype C as the dominant circulating strain in many parts of the world, including Turkey and China, may be linked to subtle molecular advantages in these proteins [7, 13, 18]. Serological surveys have also confirmed that cattle are more commonly exposed to BPIV-3c than BPIV-3a, a finding with significant implications for vaccine strain selection, as most current vaccines are based on the BPIV-3a genotype [21].

Finally, the pathogenesis of BPIV-3 is profoundly influenced by co-infections, which are the rule rather than the exception in BRDC. Immunohistochemical studies of lung tissue from cattle with BRDC have shown that BPIV-3 is the predominant viral agent, often found in co-infection with Mycoplasma bovis [6]. Crucially, unlike bovine respiratory syncytial virus (BRSV), BPIV-3 and M. bovis antigens persist in chronic cases of BRDC, suggesting that BPIV-3 infection may cause long-lasting impairment of pulmonary defense mechanisms, such as mucociliary clearance and alveolar macrophage function [6]. This chronic persistence creates a permissive environment for secondary bacterial invaders, driving the progression from viral pneumonia to severe, often fatal, suppurative bronchopneumonia. The molecular basis for this synergy likely involves BPIV-3-induced damage to the respiratory epithelium, exposing basement membrane receptors for bacterial adherence, and the immunomodulatory effects of the virus, which can suppress neutrophil and macrophage function. This complex interplay between viral and bacterial pathogens at the molecular level is what ultimately determines the severity and outcome of BRDC.

Epidemiology and Risk Factors for BPIV-3 Infection

Bovine parainfluenza virus 3 (BPIV-3) is a ubiquitous and economically significant respiratory pathogen of cattle, exhibiting a global distribution that underscores its role as a cornerstone of the bovine respiratory disease complex (BRDC). The epidemiology of BPIV-3 is characterized by high seroprevalence rates across diverse production systems, yet the manifestation of clinical disease is heavily modulated by a complex interplay of viral genotype, host factors, environmental stressors, and management practices. Understanding these epidemiological patterns and the specific risk factors that precipitate clinical outbreaks is paramount for designing effective control strategies, including vaccination protocols and biosecurity measures. This section provides a comprehensive analysis of the global distribution, prevalence, transmission dynamics, and the multifactorial risk factors that govern BPIV-3 infection.

Global Distribution and Seroprevalence

BPIV-3 infection is enzootic in cattle populations worldwide, with serological surveys consistently demonstrating that a majority of animals have been exposed to the virus by the time they reach adulthood. The World Organisation for Animal Health (WOAH) recognizes BPIV-3 as a primary viral agent within the BRDC, and its control is a priority for many national veterinary services. The true prevalence, however, varies significantly based on geographic region, production type (beef versus dairy), herd size, and vaccination history.

In South America, a cross-sectional study in Villavicencio, Colombia, reported an animal-level seroprevalence of 85.9% for parainfluenza virus 3 (PI-3), with herd-level seroprevalence exceeding 95% across all tested viruses, including bovine herpesvirus 1 (BoHV-1) and bovine respiratory syncytial virus (BRSV) [3]. This indicates near-universal exposure within herds, a pattern echoed in a study from Paraná, Brazil, where 96.8% of unvaccinated dairy cows and 100% of herds were seropositive for BPIV-3 [24]. These findings from high-producing dairy regions confirm that BPIV-3 circulates endemically even in the absence of clinical vaccination, maintaining a constant source of infection for naïve animals.

In Europe, similar patterns emerge. A comprehensive study in Serbia found a true animal-level seroprevalence of 84.59% for BPIV-3, with universal seropositivity across all 65 sampled dairy farms [4]. In Sweden, a longitudinal study of dairy herds revealed that 48% of calves were seropositive to parainfluenza virus 3 (PIV-3) by approximately 7 months of age, with 38% of seronegative animals seroconverting by 15 months, demonstrating intense viral circulation in young stock [22]. In Norway, a national survey of dairy calves estimated a seroprevalence of 50.2% for PIV-3, highlighting its widespread nature even in countries with relatively isolated cattle populations [29]. A study in Finland also confirmed PIV-3 as a common pathogen based on serological findings in herds with respiratory disease [26]. In Turkey, a serosurvey of domestic ruminants found that 56.2% of cattle were seropositive for BPIV-3, with goats showing the highest overall seropositivity at 63% [21]. This study also provided the first comparative analysis of genotype-specific seroprevalence, revealing that neutralizing antibodies against BPIV-3c (34.3%) were significantly more common than those against BPIV-3a (24.3%), suggesting differential circulation or immunogenicity of these genotypes [21].

In North America, BPIV-3 is a well-established component of the BRD pathogen complex. A study utilizing viral metagenomics on nasal swabs from feedlot cattle upon arrival in western Canada detected BPIV-3 in 10.3% of animals, a prevalence lower than that of bovine coronavirus (45.2%) but still significant [36]. This detection rate likely underestimates true exposure, as the study focused on active viral shedding at a single time point. Serological evidence from a study of wood bison (Bison bison athabascae) in Canada, a species closely related to cattle, revealed an 87% seroprevalence for BPIV-3, confirming that the virus circulates even in isolated, reintroduced wildlife populations [30]. In Asia, a large-scale epidemiological investigation in northern China (2022-2024) identified BPIV-3 as one of the dominant viral pathogens in Holstein calves with BRDC, with pronounced seasonal peaks in colder months [18]. Phylogenetic analysis of Chinese isolates revealed a connection to international strains, particularly BPIV-3c, indicating global pathogen flow [18]. In India, a study of pneumonic young cattle and buffaloes detected BPIV-3 in 3.69% of cases by RT-PCR, marking the first molecular confirmation of the virus in the country [34]. In Turkey, the first isolation of BPIV-3c from a severe respiratory outbreak in calves was reported, with eight deaths among 20 affected animals, underscoring the potential for high morbidity and mortality in naïve populations [7]. A separate study in eastern Turkey detected BPIV-3 RNA in 1.93% of samples from cattle with respiratory signs, further confirming its presence [5].

Transmission Dynamics and Shedding

BPIV-3 is primarily transmitted via the respiratory route through direct contact with infected animals or inhalation of aerosolized droplets. The virus replicates extensively in the epithelial cells of the upper and lower respiratory tract, leading to high viral titers in nasal secretions. The shedding course is critical for understanding outbreak dynamics. A study using a modified-live intranasal vaccine demonstrated that vaccinated calves shed both BRSV and BPIV-3 in nasal discharges for up to 8 days post-vaccination, with individual variability in the duration and magnitude of shedding [17]. This highlights that even attenuated vaccine strains can replicate and be excreted, although the risk of transmission to unvaccinated cohorts is generally considered low. In natural infections, the peak of viral shedding typically coincides with the onset of clinical signs, and the virus can be detected for 7-14 days. The ability of BPIV-3 to persist in the environment is limited, as it is an enveloped virus susceptible to desiccation and common disinfectants. However, the high density of animals in modern production systems facilitates rapid transmission, making BPIV-3 a near-constant presence in many herds.

Host-Level Risk Factors

The transition from subclinical infection to overt disease is governed by several host-specific factors. Age is a consistently identified risk factor. Young calves, particularly those between 2 and 12 months of age, are most susceptible to severe clinical disease. This is due to the waning of maternally derived antibodies (MDA) and the immaturity of their adaptive immune system. A multivariate analysis in Turkey identified age as a significant risk factor for BPIV-3 infection [2]. Similarly, a study in Colombia found that animals over 3 years of age had a higher seroprevalence, which likely reflects cumulative lifetime exposure rather than increased susceptibility [3]. The same study identified female sex as a simultaneous risk factor for BPIV-3, BoHV-1, and BRSV, potentially due to physiological stress associated with parturition and lactation [3]. Breed may also play a role; the Colombian study found that the Brahman breed was a risk factor for BoHV-1, but this was not specifically identified for BPIV-3 [3]. The presence of pre-existing or concurrent disease is a powerful predisposing factor. Calves with a history of diarrhea have a significantly increased risk of developing respiratory disease, including BPIV-3 infection, as demonstrated in a Norwegian study (Hazard Ratio = 3.9) [29]. This is likely due to the immunosuppressive effects of enteric infections and the associated metabolic and nutritional stress.

Environmental and Management Risk Factors

The most critical and modifiable risk factors for BPIV-3 infection are those related to the environment and herd management. These factors are often the primary drivers that tip the balance from endemic stability to clinical outbreak.

Housing and Ventilation: Poor air quality is a potent risk factor. A study in Turkey identified qualitative air quality as a significant factor in multivariate analysis for BPIV-3 infection [2]. Inadequate ventilation leads to the accumulation of ammonia, dust, and airborne pathogens, which impair mucociliary clearance and damage the respiratory epithelium, facilitating viral invasion. The same study identified housing type as a risk factor in univariate analysis [2]. Calves housed in enclosed, poorly ventilated barns are at greater risk than those in open sheds or on pasture. The type of bedding also plays a role; a multivariate analysis for BRSV (and by association, for the BRDC environment) identified bedding type as a significant risk factor [2]. Deep, dry bedding can reduce ammonia levels, while wet, contaminated bedding promotes pathogen survival and aerosolization.

Herd Size and Density: Herd size is a well-established risk factor for respiratory disease. Larger herds have a higher likelihood of introducing and maintaining multiple pathogens. In Turkey, large-capacity dairy farms had significantly higher seroprevalence for BRSV and BoHV-1 compared to small farms, and this principle applies to BPIV-3 as well [27]. In Norway, a herd size of more than 50 cow-years was associated with an 8.2-fold increase in the risk of respiratory disease in calves [29]. High animal density facilitates direct contact and increases the concentration of infectious aerosols. A study in Serbia found that medium-sized and large farms exhibited higher levels of seropositivity for BRSV and BHV-1 compared to small farms, a pattern that is consistent with the dynamics of BPIV-3 [4].

Transportation and Commingling: The stress of transportation is one of the most significant risk factors for BRD, and BPIV-3 is a key player in this context. A study tracking beef steers shipped from France to Italy found that the number of animals positive for BPIV-3 and other pathogens increased dramatically after transport [19]. The study identified animal transport as a risk factor for BPIV-3 in univariate analysis [2]. The physical stress of loading, unloading, and the journey itself, combined with the psychological stress of novel environments and social regrouping, leads to immunosuppression, primarily through elevated cortisol levels. Commingling animals from multiple sources at feedlots or sales yards ensures a diverse pathogen exposure, overwhelming the immune system of stressed animals.

Quarantine and Biosecurity: The failure to quarantine newly arrived animals is a major risk factor for introducing BPIV-3 into a naïve herd. A study in Turkey identified quarantine status as a risk factor for BRSV infection, and the same principle applies to BPIV-3 [2]. The duration from infection onset to sampling was also identified as a risk factor, likely reflecting delays in diagnosis and isolation of sick animals, allowing for further spread [2]. The purchase of animals was identified as a risk factor for BRSV and BoHV-1 in Colombia, and this is a well-recognized route for introducing BPIV-3 into closed herds [3].

Seasonality: BPIV-3 infections exhibit a pronounced seasonality, with peaks in the colder months. A large-scale study in northern China confirmed that viral pathogens, including BPIV-3, had pronounced seasonal peaks in colder months [18]. In Turkey, the period of disease occurrence was identified as a risk factor for BRSV, and the same seasonal pattern holds for BPIV-3 [2]. Cold weather forces animals indoors, increasing stocking density and reducing ventilation. Additionally, cold stress can directly impair immune function, and the lower ambient humidity may enhance the survival of aerosolized virus particles.

Co-infection and the Role of BPIV-3 in BRDC

BPIV-3 rarely acts alone. Its epidemiological significance is amplified by its role as a primary pathogen that predisposes the lung to secondary bacterial infections. A landmark study in Switzerland using immunohistochemistry on 104 autopsy cases of BRDC found that BPIV-3 was the predominant agent, present as a single infection in 39 cases and in co-infection with Mycoplasma bovis in another 39 cases [6]. Crucially, this study demonstrated that BPIV-3 and M. bovis persisted in chronic BRDC, suggesting an ongoing impairment of pulmonary defense mechanisms [6]. This synergistic relationship is a key epidemiological feature. The virus damages the ciliated epithelium and suppresses alveolar macrophage function, creating an ideal environment for opportunistic bacteria like Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni to colonize the lower respiratory tract. A study in Brazil found that while BPIV-3 was detected in only 8.3% of pneumonic lungs by immunohistochemistry, it was often part of mixed infections with BVDV, MCFV, and M. bovis [35]. In a study of aborted bovine fetuses in Brazil, BPIV-3 was identified in 2.7% of cases, indicating its potential role in reproductive failure, though BRSV and BVDV were more common [20]. A detailed case report from Uruguay confirmed that BPIV-3 genotype A can cause fetal pathology, including necrotizing bronchiolitis and interstitial pneumonia in an aborted Holstein fetus [8]. This expands the epidemiological impact of BPIV-3 beyond the respiratory tract.

Genotype-Specific Epidemiology

The existence of three distinct genotypes of BPIV-3 (A, B, and C) adds another layer of complexity to its epidemiology. While all three genotypes can cause disease, their geographic distribution and prevalence differ. Genotype A is considered the prototype and is globally distributed. Genotype B has been reported primarily in Asia, with a notable isolation from cattle in China [13]. Genotype C appears to be highly prevalent and is increasingly recognized worldwide. The first isolation of BPIV-3c in Turkey was associated with a severe outbreak causing 40% mortality in calves [7]. The serosurvey in Turkey that compared A and C genotypes found that neutralizing antibodies against BPIV-3c were significantly more prevalent than those against BPIV-3a, suggesting that genotype C may be more transmissible or immunogenic [21]. This has critical implications for vaccine efficacy, as most commercial vaccines are based on genotype A. The potential for incomplete cross-protection between genotypes could explain vaccine failures in the field and underscores the need for ongoing molecular surveillance to ensure vaccine strains match circulating field strains.

Molecular and Cellular Determinants of Susceptibility

Recent advances in functional genomics have begun to unravel the host factors that determine susceptibility to BPIV-3 infection at a cellular level. A genome-scale CRISPR screen in bovine kidney cells identified several host genes essential for BPIV-3a replication, including WNT5A, SLC16A13, and SELENON [1]. WNT5A was found to be involved in both viral adhesion and internalization, while SLC16A13 participated solely in internalization [1]. These findings suggest that host genetic variation in these pathways could influence individual animal susceptibility to infection. Furthermore, the virus utilizes specific endocytic pathways for entry, which can vary by cell type. In MDBK cells, BPIV-3 enters via clathrin-mediated endocytosis and macropinocytosis in a pH-dependent manner [12]. In HeLa cells, entry is solely via clathrin-mediated endocytosis [11]. The epidermal growth factor receptor (EGFR) has been identified as a critical host-entry cofactor that promotes BPIV-3 uptake by activating downstream signaling pathways (PI3K-Akt and ERK1/2) that remodel the actin cytoskeleton [31]. These molecular insights provide a foundation for understanding why certain animals or populations may be more permissive to infection and offer potential targets for novel antiviral interventions.

Clinical Manifestations and Pathological Features

Bovine parainfluenza virus 3 (BPIV-3) is a pervasive respiratory pathogen of cattle, exhibiting a spectrum of clinical presentations that range from subclinical infection to severe, life-threatening pneumonia. The clinical outcome is profoundly influenced by a complex interplay of host factors, including age, immune status, and concurrent infections, and environmental stressors such as transportation, overcrowding, and inadequate ventilation. Understanding the full breadth of clinical manifestations and the corresponding pathological alterations is essential for accurate diagnosis, effective management, and the development of targeted intervention strategies.

Acute Clinical Manifestations

The clinical onset of BPIV-3 infection is typically acute, occurring after an incubation period of approximately 2 to 6 days. The earliest signs are often nonspecific and include pyrexia, with temperatures frequently exceeding 40°C, accompanied by depression, anorexia, and a marked reduction in feed intake [7, 19]. Ocular and nasal discharges are cardinal features; the nasal discharge initially appears serous but rapidly progresses to a mucopurulent consistency as secondary bacterial invaders exploit the virus-induced compromise of the respiratory epithelium [7, 10]. Calves and young stock, particularly those between 1 and 2 years of age, are most severely affected, exhibiting tachypnea, dyspnea, and an increased respiratory rate that is often audible as wheezing or abnormal breath sounds on auscultation [7, 10]. A deep, productive cough is a frequent complaint, further reflecting the involvement of the lower respiratory tract [37, 40]. In uncomplicated cases, clinical signs may resolve within 7 to 10 days. However, the virus’s capacity to immunosuppress the host and damage the mucociliary escalator frequently precipitates secondary bacterial pneumonia, dramatically worsening the prognosis and extending the clinical course. This is particularly evident in the context of bovine respiratory disease complex (BRDC), where BPIV-3 acts as a primary inciting agent, paving the way for bacterial pathogens such as Mannheimia haemolytica, Pasteurella multocida, and Mycoplasma bovis [6, 28].

The severity of disease is markedly exacerbated by environmental and management-related risk factors. Transport, a major stressor, has been shown to significantly increase the shedding of BPIV-3 and other respiratory pathogens, with the number of clinically affected animals and the prevalence of co-infections rising dramatically immediately following a journey [19]. Housing type, poor ventilation, and suboptimal air quality are independent risk factors for BPIV-3 infection, underscoring the importance of environmental management in disease control [2]. Furthermore, seroprevalence studies from diverse global regions, including Colombia, Serbia, Turkey, and Brazil, consistently report high rates of BPIV-3 exposure, with animal-level seropositivity often exceeding 85% [3, 4, 24, 27]. This ubiquitous circulation highlights the constant threat of clinical disease, particularly in populations where immunity is waning or in naïve animals introduced to an endemic herd. The virus does not discriminate significantly between beef and dairy operations, although the risk factors and management practices may differ, influencing the timing and severity of outbreaks [2, 4].

Gross Pathological Findings

The macroscopic lung lesions associated with BPIV-3 infection are characteristic of a viral bronchiolitis and interstitial pneumonia, often complicated by secondary bacterial bronchopneumonia. Upon postmortem examination, the lungs fail to collapse properly and are diffusely firm, heavy, and rubbery to the touch. The classic cranioventral distribution of consolidation is observed, but the affected areas are often more extensive in severe cases, involving the cardiac, apical, and intermediate lobes [34]. The cut surface of affected parenchyma is typically red to dark red, moist, and meaty, with a notable absence of the normal spongy texture. In cases of acute infection, interlobular septa are often visibly distended by edema, contributing to a characteristic marbled appearance. Fibrinous pleuritis may be present, particularly when secondary bacterial invaders are involved, with strands of fibrin adherent to the visceral pleura.

In fatal, uncomplicated viral pneumonia, the lungs are described as diffusely reddened, rubbery, and unexpanded, with a solid, meaty consistency that is readily apparent on palpation [8]. Interstitial emphysema, presenting as small gas-filled bubbles within the interlobular septa and subpleural space, is a common finding, resulting from the trapping of air due to bronchiolar obstruction and the subsequent alveolar rupture [39]. This emphysema can be extensive, leading to the formation of bullae and, in severe instances, mediastinal emphysema and pneumothorax. The regional lymph nodes, particularly the bronchial and mediastinal lymph nodes, are typically enlarged, edematous, and congested, reflecting the local immune response to the viral infection. It is critical to note that these gross lesions are not pathognomonic for BPIV-3; they overlap considerably with lesions caused by bovine respiratory syncytial virus (BRSV), bovine herpesvirus 1, and other viral pneumonias, underscoring the necessity of confirmatory diagnostic testing [38].

Histopathological and Ultrastructural Features

The microscopic lesions of BPIV-3 infection provide a more definitive picture of the virus’s cytopathic effects and the host’s inflammatory response. The hallmark histopathological finding is a bronchointerstitial pneumonia, characterized by a pronounced necrotizing bronchiolitis and alveolitis [8, 34, 38]. The bronchiolar epithelium undergoes necrosis and sloughing, with cellular debris accumulating within the airway lumens. The alveolar septa are markedly thickened by the infiltration of mononuclear cells, primarily macrophages and lymphocytes, along with congestion and edema [34, 35]. The alveolar spaces themselves are frequently filled with a mixed inflammatory exudate, comprising mononuclear cells, sloughed epithelial cells, and a fibrinous proteinaceous fluid [8].

A particularly striking and diagnostically relevant feature of BPIV-3 infection is the presence of syncytial cells, or multinucleated giant cells, both within the bronchiolar and alveolar lumens and lining the alveolar walls [8, 34]. These syncytia are formed by the fusion of infected epithelial cells, a direct consequence of the fusion (F) glycoprotein expressed on the cell surface. Their identification is highly suggestive of a paramyxovirus infection and is a key feature differentiating BPIV-3 from other viral pathogens. In cases of chronic infection, a persistent and aggressive inflammatory response is observed. BPIV-3 antigen can be detected by immunohistochemistry (IHC) within bronchiolar and alveolar epithelial cells, as well as within the syncytial cells, confirming active viral replication at the site of injury [6, 8, 20]. Unlike BRSV, which tends to be cleared more rapidly, BPIV-3 and M. bovis have been shown to persist in the lungs of cattle with chronic BRDC, suggesting an ongoing impairment of pulmonary defense mechanisms that contributes to the chronicity of the disease [6]. Hyperplasia of type II pneumocytes is a common reparative response, as the lung attempts to repopulate the damaged alveolar epithelium [34].

Fetal Pathology and Reproductive Manifestations

While BPIV-3 is primarily recognized as a respiratory pathogen, its ability to cross the placenta and cause fetal infection is a significant, albeit less appreciated, clinical manifestation. Natural cases of BPIV-3-associated abortion are well-documented, and the virus has been isolated from the tissues of aborted fetuses, providing direct evidence of its role as a reproductive pathogen [8, 20]. Detailed pathological examination of spontaneously aborted fetuses reveals a pattern of lesions that mirrors the fulminant nature of the infection in the neonate. The fetal lungs are diffusely reddened, rubbery, and unexpanded, failing to float in formalin. Histologically, there is a severe necrotizing bronchiolitis and alveolitis, with abundant intraluminal fibrin exudate and the presence of numerous syncytial cells, identical to those seen in the postnatal lung [8]. A non-suppurative peribronchiolitis and perivascular interstitial pneumonia is consistently observed. The virus’s tropism extends beyond the respiratory tract in the fetus; immunohistochemistry has detected BPIV-3 antigen within the epithelium of the small intestine, which can show multifocal necrotizing cryptitis with occasional necrotic syncytial enterocytes [8]. This extra-respiratory distribution suggests that viremia is a common feature of fetal infection. The detection of BPIV-3 nucleic acid and antigen in fetal tissues, including lung and small intestine, confirms that the virus reaches the fetus via the transplacental route, likely through the hematogenous spread from an infected dam [8, 20]. The inflammatory response and tissue destruction observed in the fetus are consistent with a direct viral cytopathic effect, rather than a secondary immune-mediated process, and can result in fetal death and expulsion. This capacity for in utero infection has implications for reproductive health and herd biosecurity, as it represents a potential pathway for the maintenance of the virus within a herd across generations.

Immunopathogenesis and Viral Persistence

The clinical manifestations of BPIV-3 are not solely a result of direct viral cytotoxicity but are also shaped by the host’s immune response and the virus’s sophisticated immune evasion strategies. BPIV-3, like other paramyxoviruses, has evolved mechanisms to subvert the host’s innate antiviral defenses. The virus has been demonstrated to inhibit the production of type I interferons (IFN-α/β), which are critical for establishing an antiviral state in infected and neighboring cells [32]. This suppression allows the virus to replicate more efficiently during the early stages of infection. However, this same inhibition may also delay the clearing of the virus, prolonging the period of viral shedding and increasing the opportunity for secondary bacterial infections. The P gene of BPIV-3 is uniquely structured, expressing three distinct proteins (P, V, and D) from a single mRNA editing site [9]. The V protein, in particular, is a known interferon antagonist in other paramyxoviruses, and its expression likely plays a key role in the virus’s ability to dampen the host’s interferon response in cattle.

The persistence of BPIV-3 antigen in chronic lesions, often in co-infection with M. bovis, points to a complex immunological dynamic [6]. The virus may contribute to a state of local immunosuppression, impairing the function of pulmonary alveolar macrophages and other immune effectors. This compromises the lung’s ability to clear not only the virus itself but also opportunistic bacterial pathogens that are the ultimate cause of severe clinical disease and mortality. The entry of BPIV-3 into host cells is a multistep process that relies on host cell machinery, including clathrin-mediated endocytosis and macropinocytosis, processes that are dependent on actin dynamics and signaling through the epidermal growth factor receptor (EGFR) and downstream effectors like PI3K-Akt and ERK1/2 [11, 12, 31]. Understanding these host cell dependencies provides potential targets for antiviral therapies, as inhibiting these pathways can block viral entry. Furthermore, genome-wide CRISPR screens have identified host factors such as WNT5A and SLC16A13 that are essential for BPIV-3 replication, offering novel avenues for therapeutic intervention [1]. The interplay between the virus’s cytopathic effects, its ability to suppress innate immunity, and the resulting inflammatory cascade ultimately dictates the severity of the clinical syndrome.

Diagnostic Approaches and Molecular Detection of BPIV-3

The accurate and timely diagnosis of bovine parainfluenza virus 3 (BPIV-3) infection is a cornerstone of effective bovine respiratory disease complex (BRDC) management, surveillance, and control. Given the multifactorial etiology of BRDC, where viral agents like BPIV-3 frequently act as primary initiators of respiratory pathology, predisposing the lower respiratory tract to secondary bacterial colonization [2, 6, 42], diagnostic approaches must be both sensitive and specific. The diagnostic landscape for BPIV-3 has evolved considerably from traditional methods of virus isolation and serology to sophisticated molecular platforms capable of simultaneous pathogen detection, genotyping, and quantification. This section provides an exhaustive examination of the diagnostic armamentarium available for BPIV-3, detailing the principles, applications, limitations, and interpretative nuances of each modality, with a particular emphasis on molecular detection strategies that have revolutionized veterinary diagnostic virology.

Traditional Diagnostic Methods: Virus Isolation and Antigen Detection

Historically, virus isolation (VI) has been regarded as the gold standard for the definitive diagnosis of BPIV-3 infection. The virus exhibits a pronounced cytopathic effect (CPE) in permissive cell lines, most notably Madin-Darby Bovine Kidney (MDBK) cells [7, 10, 13]. Upon successful isolation, characteristic CPE develops progressively, typically manifesting as cell rounding, clumping, and the formation of syncytia or multinucleated giant cells, followed by complete detachment of the cell monolayer [10, 13]. In a study characterizing the first BPIV-3c isolate from Turkey, lung specimens from a deceased calf were inoculated onto MDBK cells, and subsequent whole genome sequencing confirmed the isolate’s genotype [7]. Similarly, work in Iraq demonstrated that camel-derived PIV-3 produced discernible CPE after three successive passages in bovine kidney cell culture, with titers increasing from 10^-3/0.05 mL at the third passage to 10^-5/0.05 mL by the fifth and sixth passages [10]. Despite its definitive nature, VI is fraught with logistical limitations: it is time-consuming, often requiring days to weeks for CPE development; it is dependent on the collection of viable virus, which necessitates stringent cold-chain management during transport; and its sensitivity is inferior to modern molecular assays, particularly when samples contain low viral loads or are degraded [41, 42]. Consequently, VI has been largely supplanted by molecular techniques in routine diagnostic settings, though it remains invaluable for archiving isolates, characterizing novel genotypes, and conducting detailed virological research [13].

Antigen detection methods, including direct immunofluorescence antibody tests (d-FAT) and enzyme-linked immunosorbent assays (ELISA), offer more rapid alternatives to VI. Immunohistochemistry (IHC) applied to formalin-fixed, paraffin-embedded (FFPE) lung tissue has proven exceptionally useful for retrospective studies and for establishing the intralesional presence of BPIV-3 antigen. In a comprehensive postmortem study of 104 Swiss cattle with BRDC, IHC identified BPIV-3 as the predominant viral agent, detected as a single infection in 39 cases and in coinfection with Mycoplasma bovis in an additional 39 cases [6]. Importantly, this study demonstrated that BPIV-3 antigen persisted in chronic lesions, suggesting an ongoing impairment of pulmonary defense mechanisms [6]. In Indian cattle and buffaloes, IHC combined with d-FAT on lung sections revealed BPIV-3 antigen distribution within bronchiolar and alveolar epithelium and within syncytial cells, correlating with histopathological findings of bronchointerstitial pneumonia [34]. The detection of BPIV-3 antigen in fetal tissues, including lung and small intestine, by IHC in a case of spontaneous abortion underscores the virus’s capacity for transplacental transmission and the utility of antigen detection in reproductive pathology [8]. Furthermore, antigen-capture ELISA has been employed for screening pneumonic lung samples, with reported prevalence rates of 11.9% for PIV-3 in Sudanese cattle [25]. While these antigen-based methods provide spatial context and are relatively rapid, their sensitivity is generally lower than that of nucleic acid amplification tests (NAATs), and they require specific antibodies that may not discriminate between closely related viral genotypes [42].

Serological Approaches: Virus Neutralization, Hemagglutination Inhibition, and ELISA

Serological diagnosis of BPIV-3 is predicated on the detection of specific antibodies, typically IgG, in serum or milk, indicating prior exposure or vaccination. The virus neutralization test (VNT) remains the serological reference standard, measuring the ability of serum antibodies to neutralize viral infectivity in cell culture. This assay is highly specific and provides a functional measure of antibody titers, which are often reported as the reciprocal of the highest serum dilution that inhibits CPE (e.g., SN50). In a large-scale Turkish serosurvey of 1,307 domestic ruminants, VNT revealed that goats harbored the highest seropositivity rate (63%), followed by cattle (56.2%), sheep (32.2%), and water buffalo (26%) [21]. Notably, this study was the first to compare neutralization rates against BPIV-3a and BPIV-3c genotypes, finding that animals were more commonly exposed to BPIV-3c (34.3% seropositivity) than to BPIV-3a (24.3% seropositivity), a finding with significant implications for vaccine efficacy given that current vaccines are predominantly based on genotype A [21, 23].

The hemagglutination inhibition (HI) assay exploits the hemagglutinin-neuraminidase (HN) glycoprotein of BPIV-3, which agglutinates erythrocytes, particularly those from guinea pigs or chickens. HI is technically simpler and less expensive than VNT, making it suitable for large-scale epidemiological surveys. However, it is less sensitive than VNT and can be affected by nonspecific inhibitors in serum. Complement fixation (CF) tests, while historically used, have largely been replaced by ELISA due to the latter’s superior throughput, objectivity, and ability to be automated [42]. Commercial and in-house indirect ELISAs (iELISA) are widely employed for seroprevalence studies. In Colombia, iELISA detected a PI-3 seroprevalence of 85.9% at the animal level and over 95% at the herd level [3]. Similarly, in a Brazilian study of unvaccinated dairy cows, virus neutralization tests yielded a striking 96.8% seropositivity for BPIV3, confirming endemic circulation [24]. In the Republic of Serbia, true seroprevalence was estimated at 84.59% [4], while in Norway, 50.2% of dairy calves over 150 days old were seropositive [29]. These data collectively illustrate the near-ubiquitous nature of BPIV-3 exposure globally.

A critical limitation of serology is the inability to distinguish between antibodies induced by natural infection and those resulting from vaccination. Furthermore, seroconversion requires a lag period of 7–14 days post-infection, rendering serology unsuitable for acute diagnosis. Paired serum samples, collected during the acute phase and again 3–4 weeks later, are essential to demonstrate a four-fold or greater rise in antibody titer, which is diagnostic of recent infection [22, 42]. Epidemiological studies using paired sera have been instrumental in elucidating infection dynamics. For instance, in Swedish dairy herds, seroconversion to PIV-3 occurred in 38% of initially seronegative calves between approximately 7 and 15 months of age, and 90–97% of animals seropositive at the first sampling remained positive at the second [22].

Molecular Detection: Conventional and Real-Time Reverse Transcription PCR

The advent of polymerase chain reaction (PCR), and specifically reverse transcription PCR (RT-PCR), has transformed the diagnosis of RNA viruses like BPIV-3. These methods offer unparalleled sensitivity, specificity, and speed, enabling the detection of viral nucleic acid directly from clinical specimens such as nasal swabs, nasopharyngeal swabs, tracheal washes, bronchoalveolar lavage fluid, and postmortem lung tissue [42]. Conventional (end-point) RT-PCR targets conserved regions of the BPIV-3 genome, most commonly the nucleocapsid (N) gene, matrix (M) gene, or fusion (F) gene, and has been used extensively for primary detection and molecular characterization [5, 7, 13, 34]. In a seminal study from Turkey, RT-PCR targeting the M gene identified BPIV-3 in 1.93% of samples, with subsequent sequencing and phylogenetic analysis clustering the strain within genotype C [5]. Sequence analysis of RT-PCR amplicons has confirmed the presence of BPIV-3 in Indian cattle and buffaloes, marking the first molecular confirmation of this virus in the country [34]. Similarly, conventional RT-PCR was instrumental in detecting BPIV-3a in fetal tissues from an aborted Holstein fetus, enabling genotype identification and expanding the known tropism of the virus [8].

Real-time quantitative RT-PCR (RT-qPCR) represents a significant technological advancement over conventional PCR. By incorporating fluorescent probes, such as TaqMan, minor groove binding (MGB), or locked nucleic acid (LNA) probes, RT-qPCR allows for the simultaneous amplification and quantification of viral RNA in a closed-tube system, eliminating post-amplification handling and reducing contamination risk [41]. The sensitivity of RT-qPCR for BPIV-3 is exceptional. Thonur et al. (2012) developed a one-step multiplex RT-qPCR (mRT-qPCR) for the simultaneous detection of BRSV, BoHV-1, and BPIV-3, achieving a detection limit of 10^2 copies of in vitro-transcribed RNA and a clinical sensitivity of 97% compared to virus isolation and immunofluorescence [41]. This assay, targeting the BPIV-3 N gene, was validated using 541 clinical samples from clinically affected animals and proved to be far more sensitive than traditional methods [41].

The diagnostic performance of RT-qPCR has been consistently demonstrated in field studies. In a comprehensive analysis of 310 beef calves upon arrival at Canadian feedlots, BPIV-3 was detected in 10.3% of deep nasal swabs using RT-qPCR [36]. In Serbian dairy farms, RT-qPCR detected BPIV-3 RNA in 10.9% of nasal swabs from animals with respiratory signs [4]. A Turkish study employing RT-PCR identified BPIV-3 in 8% of nasal swabs from 200 cattle across 24 herds [2]. In Japanese development of a broad-spectrum TaqMan-based detection system (Dembo respiratory-PCR), BPIV-3 was included as one of 16 targeted bovine respiratory pathogens, and the primer-probe sets demonstrated high sensitivity and specificity [44]. These data underscore the utility of RT-qPCR as the frontline diagnostic tool for active BPIV-3 infection.

Multiplex and High-Throughput Molecular Platforms

Given the polymicrobial nature of BRDC, diagnostic strategies that can simultaneously detect multiple pathogens from a single sample are highly advantageous. Multiplex RT-qPCR (mRT-qPCR) platforms have been developed to target the most common viral and bacterial agents implicated in BRDC. The mRT-qPCR assay described by Thonur et al. (2012) was the first to simultaneously detect BRSV, BoHV-1, and BPIV-3 using a combination of LNA, MGB, and TaqMan probes in a single reaction [41]. This approach not only conserved time and reagents but also provided critical information on co-infections, which are the rule rather than the exception in BRDC pathogenesis.

More expansive multiplex panels have since been developed. Kishimoto et al. (2017) described the "Dembo respiratory-PCR" system, a TaqMan real-time PCR assay capable of screening for 16 different bovine respiratory pathogens in a single run, including BPIV-3, BRSV, BVDV, BoHV-1, bovine coronavirus, influenza D virus, and multiple bacterial species [44]. This high-throughput approach is ideally suited for large-scale epidemiological surveillance and outbreak investigations. Similarly, a one-step mRT-qPCR assay was used to quantify 10 pathogens, including BPIV-3, BRSV, BoHV-1, BVDV, BCoV, and several bacteria, in a cross-sectional study of beef steers transported from France to Italy [19]. This study revealed that transport dramatically increased co-infection rates from 16.0% at loading to 82.8% four days after arrival, highlighting the power of multiplex molecular diagnostics to capture the dynamic nature of BRDC [19].

Advanced and Emerging Detection Technologies

Beyond RT-qPCR, several advanced molecular technologies are expanding the diagnostic horizon for BPIV-3. Recombinase-aided amplification (RAA) combined with lateral flow dipstick (LFD) assays represents a novel isothermal amplification strategy that eliminates the need for thermal cyclers, making it suitable for point-of-care or field deployment. While a triplex RAA-LFD assay has been developed for BCoV, IBRV, and BVDV, it was tested for cross-reactivity and demonstrated no cross-reaction with BPIV-3, confirming the specificity of the assay [43]. This technology could be adapted for BPIV-3 detection in resource-limited settings, offering results in under 20 minutes at a constant temperature of 39°C.

CRISPR/Cas9-based screening has emerged as a powerful tool for identifying host factors essential for BPIV-3 replication. Using a bovine genome-wide CRISPR/Cas9 knockout library in MDBK cells, Geng et al. (2025) systematically identified host genes required for BPIV-3a infection, including WNT5A, SLC16A13, and SELENON [1]. While primarily a research tool, this approach has diagnostic implications by revealing host-pathogen interaction networks that could serve as biomarkers of infection or targets for antiviral therapy.

Viral metagenomic sequencing using platforms such as Oxford Nanopore offers an unbiased approach to characterize the entire nasal virome of cattle. When applied to 310 deep nasal swabs from feedlot cattle, this technique identified BPIV-3 in 10.3% of samples, along with other viruses including bovine coronavirus, bovine rhinitis B virus, enterovirus E, and influenza D virus [36]. Metagenomic sequencing provides a comprehensive snapshot of the viral community and can detect unexpected or emerging pathogens without a priori selection of targets.

Whole genome sequencing (WGS) of BPIV-3 isolates has become increasingly accessible, enabling high-resolution genotyping and phylogenetic analysis. Illumina sequencing of Chinese isolates XJ21032-1 and XJ20055-3 revealed genome lengths of 15,512 bp and 15,479 bp, respectively, with phylogenetic analysis assigning them to genotypes B and C [13]. WGS is critical for monitoring the emergence of novel genotypes, tracking transboundary spread, and informing vaccine strain selection.

Finally, a highly novel approach involves the use of trained detection dogs to discriminate cell cultures infected with BPIV-3 from those infected with other viruses. In a proof-of-concept study, two dogs achieved diagnostic sensitivity of 0.850–0.967 and specificity exceeding 0.98 in detecting BVDV-infected cells, and they could differentiate BVDV from BPIV-3 and BHV-1, likely due to pathogen-specific volatile organic compound (VOC) profiles [45]. While not yet a routine diagnostic tool, this approach suggests that volatile metabolomics could be harnessed for real-time, non-invasive pathogen detection.

Diagnostic Algorithm and Sample Selection Considerations

The selection of appropriate diagnostic methods and sample types is paramount for accurate BPIV-3 diagnosis. For acute, live-animal diagnosis, RT-qPCR on nasal or nasopharyngeal swabs is the method of choice due to its high sensitivity and rapid turnaround time. Swabs should be collected within the first few days of clinical signs, as viral shedding peaks early in infection. Deep nasopharyngeal swabs may yield higher viral loads than superficial nasal swabs [19]. Bronchoalveolar lavage fluid is an alternative for lower respiratory tract sampling, but its collection is more invasive.

For postmortem diagnosis, fresh lung tissue (for RT-PCR and virus isolation) and formalin-fixed tissues (for histopathology and IHC) should be collected. IHC is particularly valuable for confirming the intralesional presence of viral antigen and for distinguishing BPIV-3 from other causes of interstitial pneumonia [6, 20, 35]. A diagnostic algorithm integrating gross pathology, histopathology, IHC, and RT-PCR has been proposed to guide the differential diagnosis of interstitial and bronchointerstitial pneumonia in cattle [38].

For serological surveillance, VNT remains the gold standard, but iELISA is preferred for large-scale surveys due to its high throughput and lower cost. Interpretation of serological results must consider vaccination history, age-related passive antibody decay, and the endemic nature of the virus. In unvaccinated populations, high seroprevalence (often >80% at the herd level)

Prevention and Control Strategies for Bovine Parainfluenza Virus 3

The mitigation of bovine parainfluenza virus 3 (BPIV-3) infection demands a multi-layered, integrated approach that transcends simple vaccination protocols. Given its ubiquitous nature, seroprevalence rates routinely exceeding 80–90% in unvaccinated herds across diverse geographies, from Colombia [3] and Serbia [4] to Brazil [24] and Canada [30], a singular intervention is insufficient. BPIV-3 functions as a primary viral initiator within the bovine respiratory disease complex (BRDC), often predisposing the lung to secondary bacterial invaders such as Mannheimia haemolytica, Pasteurella multocida, and Mycoplasma bovis [6, 18, 25]. Consequently, effective control strategies must be predicated on a deep understanding of viral pathogenesis, transmission dynamics, and the specific risk factors that potentiate outbreaks. The following sections dissect the major pillars of prevention and control, drawing upon the most recent epidemiological and molecular evidence.

### Vaccination: The Cornerstone of Immunoprophylaxis

Vaccination remains the most economically viable and logistically practical tool for managing BPIV-3 at the herd level. The immunological objective is twofold: to induce robust, long-lasting active immunity in the vaccinated animal and to bolster passive immunity in the neonate via colostral antibody transfer.

Modified-Live Virus (MLV) versus Inactivated Vaccines

The choice between MLV and inactivated (killed) vaccines involves a trade-off between immunogenicity and safety. MLV vaccines, such as Bovishield Gold 5 (Zoetis, USA) and the intranasal Rispoval RS-PI3, are generally favored for their ability to stimulate a more comprehensive immune response, encompassing both humoral (systemic IgG and mucosal IgA) and cell-mediated immunity (CMI). A pivotal study by El-Sheikh et al. (2024) demonstrated that MLV vaccination significantly upregulated the expression of interleukin-6 (IL-6) and interferon-gamma (IFN-γ) in Holstein heifers compared to an inactivated product, with the CMI response appearing earlier and with greater magnitude in the MLV group [46]. This robust CMI is critical for clearing intracellular viral replication and for establishing immunological memory.

Conversely, inactivated vaccines (e.g., Combovak-R, Hiprabovis-4) are valued for their safety profile, they cannot revert to virulence or cause vaccine-induced shedding, and their lower cost [23]. However, they typically require an adjuvant and a booster dose to achieve protective titers, and they are less effective at stimulating the mucosal immunity essential for blocking viral entry at the respiratory epithelium. Smirnova et al. (2026) note that while livestock farms often prefer inactivated vaccines for their low allergenicity, live vaccines contribute to "more stable and long-lasting immunity" [23].

The Critical Role of the Delivery Route: Intranasal versus Parenteral

The route of administration is a decisive factor in vaccine efficacy. Intranasal (IN) vaccination offers a distinct immunological advantage: it directly targets the nasopharyngeal mucosa, the primary site of BPIV-3 replication and shedding. IN MLV vaccines, such as Rispoval RS-PI3, induce a rapid, local IgA response and stimulate innate immune mechanisms, including the production of type I interferons at the portal of entry. Research by Socha et al. (2013) demonstrated that following IN vaccination, calves shed vaccine virus for approximately 8 days, a process that mimics a subclinical infection and effectively primes the local immune system [17]. This local immunity can provide a "firebreak," preventing the virus from amplifying and spreading to the lower respiratory tract.

Parenteral (intramuscular or subcutaneous) administration, in contrast, primarily generates systemic IgG. While this IgG can transudate into the respiratory tract, it is less efficient at preventing initial viral attachment and entry compared to secretory IgA at the mucosal surface. Some studies suggest that a combined approach, using both IN and parenteral vaccines, may result in the most robust immunity, leveraging the strengths of both routes [23].

Genotype Mismatch: A Looming Threat to Vaccine Efficacy

A critical and often overlooked challenge is the antigenic diversity among BPIV-3 genotypes. Three major genotypes have been identified: A (BPIV-3a), B (BPIV-3b), and C (BPIV-3c). Most commercially available vaccines, particularly older formulations, are based on the BPIV-3a genotype [21]. However, epidemiological surveillance is increasingly revealing the dominance of BPIV-3c in many regions, including Turkey, China, and parts of Europe [5, 7, 13, 18].

A landmark serosurvey by Muftuoglu et al. (2021) in Turkish ruminants directly compared neutralizing antibody titers against BPIV-3a and BPIV-3c. The study found that seropositivity rates against BPIV-3c (34.3%) were significantly higher than those against BPIV-3a (24.3%), suggesting that natural exposure to BPIV-3c is more common [21]. This raises a troubling question: do vaccines derived from genotype A provide adequate cross-protection against the globally prevalent genotype C? The study explicitly states that "this finding could have significant implications as current vaccines mainly use the BPIV-3a genotype" and calls for further research to determine if "current vaccines protect against different BPIV-3 virus genotypes" [21]. This antigenic drift or shift has critical implications for vaccine design. The molecular characterization of Chinese isolates by Wang et al. (2022) revealed multiple amino acid changes in the major antigenic proteins (nucleocapsid, fusion, and hemagglutinin/neuraminidase) between genotypes B and C, providing a structural basis for potential immune escape [13]. Future vaccine development must prioritize multivalent formulations that include antigens from the circulating genotypes, particularly BPIV-3c, to ensure broad and effective coverage.

### Biosecurity and Herd Management: Modifying the Risk Landscape

Vaccination cannot succeed in a vacuum. The epidemiological data strongly emphasize that BPIV-3 infection is profoundly influenced by environmental and management-related risk factors. Controlling these factors is an indispensable component of any prevention strategy.

Air Quality, Ventilation, and Housing

BPIV-3 is an enveloped virus transmitted primarily via the aerosol and fomite routes. Overcrowding and poor ventilation create a high viral load within the barn environment. Multivariate regression analyses from a 2025 study by Küçük et al. identified air quality and ventilation as statistically significant risk factors for BPIV-3 detection [2]. The accumulation of ammonia, dust, and endotoxins from manure compromises the mucociliary escalator and the integrity of the respiratory epithelium, making cattle more susceptible to viral invasion. Control strategies must include optimizing stocking density, ensuring adequate air exchange rates (typically 4-6 air changes per hour in temperate climates), and maintaining dry, clean bedding. Bedding type itself emerged as a risk factor in the same study, likely due to its influence on microbial load and ammonia generation [2].

Age as a Biological Risk Factor

Age is a consistently identified risk factor. Multiple studies, including those from Colombia [3] and Turkey [5], indicate that seroprevalence increases with age. This is not merely a function of cumulative exposure; it also reflects the waning of maternal antibodies and the immaturity of the neonatal immune system. Calves are most vulnerable in the first few weeks of life, particularly if they receive inadequate colostrum. The risk factor analysis by Küçük et al. (2025) directly identified age as a risk in multivariate analysis [2], while data from Norway showed that calves over 150 days of age had a seroprevalence of 50.2% [29]. This suggests that control programs must focus intensely on the periparturient period, ensuring passive transfer of immunity and minimizing stress during weaning and grouping.

Transport, Commingling, and the "Shipping Fever" Paradigm

The historical term "shipping fever" for BPIV-3-associated BRD is a stark reminder of the role of stress in disease pathogenesis. The stress of transport, handling, and commingling from multiple sources causes a surge in endogenous corticosteroids, which are profoundly immunosuppressive. Padalino et al. (2021) documented a dramatic increase in BPIV-3 detection and co-infection rates in beef steers following a long journey from France to Italy. While no animals showed clinical signs at loading (T0), 82.8% were co-infected with multiple pathogens just four days after arrival (T1) [19]. The study identified weather conditions at arrival and extra stops during the journey as predisposing factors [19]. Preventive strategies here include minimizing transport time, implementing preconditioning programs (where calves are vaccinated and weaned before sale), and establishing quarantine protocols for newly arriving animals. The univariate analysis from Küçük et al. (2025) confirmed that animal transport and housing type were significant risk factors for BPIV-3 [2]. A 14-21 day quarantine period allows for the detection of sick animals and provides a window for immunity to develop post-vaccination before exposure to the resident herd.

### Advanced Diagnostic Surveillance as a Proactive Control Measure

A reactive approach, treating disease once clinical signs appear, is often too late, as the viral insult and subsequent lung damage have already occurred. Modern control relies on proactive surveillance using sensitive, specific, and rapid diagnostic tools.

Real-Time PCR and Multiplex Platforms

The advent of multiplex reverse-transcription quantitative PCR (mRT-qPCR) has revolutionized the early detection of BPIV-3. Thonur et al. (2012) developed the first mRT-qPCR assay capable of simultaneously detecting BPIV-3, BRSV, and BoHV-1. This assay demonstrated a sensitivity of 97% and could detect as few as 10² copies of viral nucleic acid, proving far superior to traditional virus isolation or indirect fluorescent antibody tests [41]. Such assays enable veterinarians to identify the specific viral agents circulating in a herd during the prodromal phase, allowing for targeted vaccination strategies and informed biosecure movement controls. Broader platforms, like the "Dembo respiratory-PCR" developed by Kishimoto et al. (2017), can screen for 16 different respiratory pathogens (viruses and bacteria) in a single run, providing a comprehensive risk profile [44]. These tests should be deployed strategically, such as on arrival samples at feedlots or during acute outbreak investigations.

Serological Profiling and Herd-Level Risk Stratification

ELISA and virus neutralization (VN) tests remain essential for determining herd-level exposure. The near-universal seropositivity for BPIV-3 reported in unvaccinated herds across the globe [4, 24] does not indicate protection; rather, it confirms endemic circulation and necessitates a review of vaccination protocols. Serological profiling of young stock (e.g., 3-7 month-old calves) can reveal the timing of infection. For instance, Hägglund et al. (2005) showed that 48% of Swedish calves were seropositive to PIV-3 by approximately 7 months of age [22]. If seroconversion is occurring earlier than expected, it suggests a breakdown in biosecurity or maternal immunity waning faster than anticipated. Regular serosurveillance, as advocated by González et al. (2025) [3], is a cornerstone of evidence-based control.

Novel Detection Methods: Volatile Organic Compounds (VOCs) and Biosensing

Cutting-edge research is exploring non-invasive biosensing methods. A fascinating study by Otto et al. (2016) demonstrated that trained detection dogs could discriminate between cell cultures infected with BVDV, BoHV-1, and BPIV-3 based on distinct volatile organic compound (VOC) profiles. The dogs exhibited a diagnostic sensitivity of 85-97% and specificity of 98-99% for BVDV detection [45]. While still in the experimental phase, this concept of "real-time mobile pathogen sensing" could lead to the development of electronic "noses" that sniff out BPIV-3 in barn air before clinical signs manifest, enabling instantaneous intervention.

### Host-Directed and Antiviral Strategies: The Next Frontier

The limitation of vaccines, particularly the genotype mismatch issue and the lag time to immunity, has spurred research into alternative, host-directed therapeutic and prophylactic strategies.

Targeting Viral Entry Pathways

Understanding the molecular mechanisms of BPIV-3 entry has revealed druggable targets. Pan et al. (2021, 2022) demonstrated that BPIV-3 enters MDBK cells via clathrin-mediated endocytosis and macropinocytosis, processes that are dependent on epidermal growth factor receptor (EGFR) signaling [12, 31]. The virus activates EGFR, which in turn activates downstream effectors like PI3K-Akt and ERK1/2, leading to actin rearrangement necessary for macropinocytosis [31]. Specific inhibitors of EGFR (e.g., gefitinib) or its downstream mediators (e.g., Rac1/Pak1 inhibitors) significantly reduce viral entry [12, 31]. While these agents are not yet licensed for veterinary use, they represent a potential class of prophylactic or early therapeutic drugs for high-risk animals during an outbreak.

Exploiting the Interferon System

Exogenous type I interferons (IFN-α and IFN-τ) have shown remarkable prophylactic potential against parainfluenza viruses. Sun et al. (2022) demonstrated that pretreatment of MDBK cells with caprine or bovine IFN-α and IFN-τ effectively inhibited subsequent BPIV-3 replication, with the protective effect lasting up to one week at a low concentration of 0.1 μg/mL [32]. Importantly, the interferons were effective only when administered before infection, they lacked therapeutic efficacy if given post-infection. This suggests a strategy for "pharmacological prophylaxis" during high-risk periods (e.g., prior to transport or commingling). The study also showed that BPIV-3 infection itself inhibits the natural

Genetic Diversity and Antigenic Variation Among BPIV-3 Subtypes

Bovine parainfluenza virus 3 (BPIV-3) exists as a genetically heterogeneous virus population, a feature that profoundly influences its epidemiology, pathogenicity, and the effectiveness of control measures. Understanding this diversity is not merely an academic exercise; it is foundational to designing robust diagnostic assays, predicting vaccine cross-protection, and anticipating the emergence of novel strains capable of escaping existing immunity. The molecular architecture of BPIV-3, a member of the genus Respirovirus within the family Paramyxoviridae, provides the substrate for this variation. The virus harbors a non-segmented, negative-sense single-stranded RNA genome of approximately 15,500 nucleotides, and like other RNA viruses, its replication is mediated by an error-prone RNA-dependent RNA polymerase. This intrinsic infidelity, combined with the potential for recombination and the selective pressures exerted by host immunity and vaccination, drives the continuous evolution of the virus. Contemporary phylogenetic analyses, bolstered by whole-genome sequencing, have delineated three distinct genotypes of BPIV-3: genotype A (BPIV-3a), genotype B (BPIV-3b), and genotype C (BPIV-3c) [7, 13, 18].

The earliest recognized and most extensively studied genotype is BPIV-3a, which for decades was considered the archetype. This genotype includes the historical reference strains, such as the SF-4 strain, which have been used as the basis for many commercial vaccines globally [21, 23]. However, the application of molecular epidemiological tools has revealed a far more complex picture. A landmark study by Wang et al. [13] provided definitive genomic evidence for the co-circulation of two distinct genotypes in Chinese cattle herds. Sequencing of two field isolates, XJ21032-1 and XJ20055-3, yielded genomes of 15,512 bp and 15,479 bp, respectively. Phylogenetic analysis definitively assigned the former to genotype B and the latter to genotype C, formally confirming the presence of BPIV-3b in Chinese cattle for the first time [13]. This finding was complemented by a large-scale epidemiological investigation in northern China, which demonstrated that BPIV-3c was the dominant circulating genotype in the region, showing genetic linkage with international strains and underscoring the global flow of viral pathogens [18]. The distribution of these genotypes is not uniform. While BPIV-3a appears to have a broad, global distribution, genotype B has been reported predominantly in Asia and South America, and genotype C is now recognized as a major lineage circulating in China, Turkey, and South America, with evidence of its presence in Europe and North America as well [7, 13, 18, 21].

The biological significance of this genotypic diversity lies in the antigenic and functional variation it confers. The genomic differences between subtypes are not synonymous; they encompass multiple amino acid substitutions in key structural and non-structural proteins, most critically the major antigenic determinants: the nucleocapsid (N) protein, the fusion (F) protein, and the hemagglutinin-neuraminidase (HN) protein [13]. The HN and F glycoproteins are the primary targets of neutralizing antibodies, and sequence variations in their ectodomains can lead to subtle but consequential changes in antigenicity. This has profound implications for immunity. A pivotal comparative serosurvey conducted by Muftuoglu et al. [21] across Turkish domestic ruminants provided the first direct evidence of differential seroprevalence between genotypes A and C. By screening over 1,300 sera from cattle, sheep, goats, and water buffalo using a standard virus neutralization assay, they found that overall seropositivity was significantly higher against BPIV-3c (34.3%) than against BPIV-3a (24.3%) [21]. This disparity suggests that the two genotypes are antigenically distinct enough to be recognized differently by the host immune system, and critically, it raises the possibility that immunity derived from natural infection or vaccination with one genotype may not confer optimal protection against a heterologous challenge. Since most currently licensed vaccines are based on the BPIV-3a genotype (e.g., SF-4 strain), these findings highlight a potential gap in vaccine efficacy in regions where BPIV-3c is prevalent [21, 23].

The molecular mechanisms driving this antigenic variation are rooted in the virus's evolutionary strategy. The genome-wide substitutions between genotypes are not randomly distributed. Comprehensive genomic comparisons have identified clusters of changes in the N, F, and HN proteins, with the HN gene often exhibiting the highest degree of variability [13]. The HN protein is a multifunctional molecule responsible for receptor binding, neuraminidase activity, and fusion promotion. Amino acid changes in its antigenic sites can alter the affinity for sialic acid receptors or subtly reshape the epitopes recognized by neutralizing antibodies, allowing escape from the host's humoral response. Similarly, variations in the F protein, which mediates membrane fusion, can affect both fusogenicity and the stability of the prefusion conformation, potentially influencing the virus's ability to spread cell-to-cell and its sensitivity to antibody-mediated neutralization. Even the internal proteins, such as the N and P proteins, are not immune to variation; the P gene itself is a site of remarkable complexity, where a single mRNA editing site can express all three reading frames (P, V, and D) through a unique and broad distribution of G insertions, a mechanism distinct from that of related paramyxoviruses [9]. This offers an additional layer of potential for functional variation.

The epidemiological and pathobiological consequences of this genetic diversity are becoming increasingly apparent. Beyond antigenicity, genetic changes can influence viral fitness and host tropism. For instance, a seminal study using CRISPR/Cas9 screening identified host factors, including WNT5A, SLC16A13, and SELENON, that are essential for the replication of both BPIV-3a and BPIV-3c [1]. While these factors are conserved across subtypes, suggesting a common dependency on certain host pathways, subtle differences in the efficiency of utilizing these pathways may exist. Furthermore, the association of specific genotypes with distinct clinical outcomes, such as the documented ability of BPIV-3a to cause fetal pathology in aborted Holstein fetuses [8], warrants investigation into whether other genotypes display similar or enhanced virulence. The detection of BPIV-3 in diverse hosts beyond cattle, including camels in Iraq, goats, sheep, and even wood bison in Canada, underscores the virus's ability to cross species barriers [10, 21, 30]. The genetic relatedness of these non-bovine isolates to the established bovine genotypes is a critical area for ongoing surveillance, as the emergence of a strain with altered host range could have repercussions for wildlife conservation and livestock health across multiple ungulate species.

The challenge posed by BPIV-3 genetic diversity extends to the realm of diagnostics. The development and validation of molecular detection tools, such as the multiplex real-time RT-PCR assays designed to detect BPIV-3, must account for this variation. Assays targeting highly conserved regions, such as the nucleoprotein gene, can still fail to detect emerging or divergent strains if the primer and probe binding sites are not rigorously aligned against a comprehensive collection of sequences from all known genotypes [41, 44]. Serological diagnosis using virus neutralization is also affected; relying on a single reference strain (e.g., BPIV-3a) for serosurveys may underestimate the true exposure rate in a population where a different genotype is circulating, as suggested by the Turkish study [21]. This has direct implications for the WOAH’s (World Organisation for Animal Health) guidelines on reporting and surveillance of bovine respiratory disease, a condition of significant economic impact globally. The FAO also recognizes the importance of understanding pathogen genetic diversity for improving food security through better animal health management.

In conclusion, the recognition of three distinct genotypes of BPIV-3, A, B, and C, each with a unique evolutionary trajectory and global distribution, has transformed our understanding of this pathogen. The amino acid differences in key antigenic proteins, particularly HN and F, create a landscape of antigenic variation that can undermine vaccine-induced immunity and lead to diagnostic blind spots. The higher seroprevalence of genotype C compared to genotype A in several populations is a sentinel signal that current vaccination strategies may require revision, potentially moving toward bivalent or multivalent vaccines that incorporate multiple circulating subtypes. The continuous monitoring of BPIV-3 genetic diversity through next-generation sequencing and phylogenetic analysis is not just recommended but essential. It is the only way to track the emergence of novel variants, assess their potential for immune escape, and ensure that both diagnostic and prophylactic tools remain effective in an ever-evolving arms race against this ubiquitous respiratory virus.

References

[1] Geng Y, Jiang C, Zhang H, Yang H, Peng Y, Chen Y, et al.. Genome-scale CRISPR screen identifies host factors associated with bovine parainfluenza virus 3 infection. Virulence. 2025. DOI: https://doi.org/10.1080/21505594.2025.2589554

[2] Küçük A, Yıldırım Y, Çetintav B. Assessment of Risk Factors Related to Environmental Factors and Herd Management for Bovine Respiratory Syncytial Virus and Bovine Parainfluenza Virus‐3 Infections Frequently Observed in Beef and Dairy Cattle. Veterinary Medicine and Science. 2025. DOI: https://doi.org/10.1002/vms3.70299

[3] González C, Briñez K, Tobon J, Corredor DWS, Bauermann FV, Barragán BLG. Cross-sectional seroprevalence study of bovine herpesvirus 1, bovine respiratory syncytial virus, and parainfluenza virus 3 in cattle from Villavicencio, Colombia. BMC Veterinary Research. 2025. DOI: https://doi.org/10.1186/s12917-024-04461-6

[4] Milićević V, Šolaja S, Glišić D, Ninković M, Milovanović B, Đorđević M, et al.. Bovine Parainfluenza Virus 3 and Bovine Respiratory Syncytial Virus: Dominant Viral Players in Bovine Respiratory Disease Complex among Serbian Cattle. Animals. 2024. DOI: https://doi.org/10.3390/ani14101458

[5] Timurkan M, Aydın H, Sait A. Identification and Molecular Characterisation of Bovine Parainfluenza Virus-3 and Bovine Respiratory Syncytial Virus - First Report from Turkey. Journal of Veterinary Research. 2019. DOI: https://doi.org/10.2478/jvetres-2019-0022

[6] Mehinagic K, Pilo P, Vidondo B, Stokar-Regenscheit N. Coinfection of Swiss cattle with bovine parainfluenza virus 3 and Mycoplasma bovis at acute and chronic stages of bovine respiratory disease complex. Journal of Veterinary Diagnostic Investigation. 2019. DOI: https://doi.org/10.1177/1040638719861686

[7] Albayrak H, Yazici Z, Ozan E, Tamer C, Wahed AAE, Wehner S, et al.. Characterisation of the First Bovine Parainfluenza Virus 3 Isolate Detected in Cattle in Turkey. Veterinary Sciences. 2019. DOI: https://doi.org/10.3390/vetsci6020056

[8] Macías-Rioseco M, Mirazo S, Uzal F, Fraga M, Silveira C, Maya L, et al.. Fetal Pathology in an Aborted Holstein Fetus Infected With Bovine Parainfluenza Virus-3 Genotype A. Veterinary Pathology-Supplement. 2018. DOI: https://doi.org/10.1177/0300985818798117

[9] Pelet T, Curran J, Kolakofsky D. The P gene of bovine parainfluenza virus 3 expresses all three reading frames from a single mRNA editing site.. EMBO Journal. 1991. DOI: https://doi.org/10.1002/j.1460-2075.1991.tb07966.x

[10] Al-Bayati HAM, Shamkhi GJ, AL-Aidy S, Gharban H. Serological Detection, Isolation and Molecular Confirmation of Parainfluenza Virus-3 in Camels, Iraq. Sumer 1. 2023. DOI: https://doi.org/10.21931/rb/css/s2023.08.01.29

[11] Pan W, Nie H, Wang H, He H. Bovine Parainfluenza Virus Type 3 (BPIV3) Enters HeLa Cells via Clathrin-Mediated Endocytosis in a Cholesterol- and Dynamin-Dependent Manner. Viruses. 2021. DOI: https://doi.org/10.3390/v13061035

[12] Pan W, Hui N, Wang H, He H. Entry of bovine parainfluenza virus type 3 into MDBK cells occurs via clathrin-mediated endocytosis and macropinocytosis in a acid-dependent manner.. Veterinary Microbiology. 2021. DOI: https://doi.org/10.1016/j.vetmic.2021.109148

[13] Wang X, Hu J, Meng F, Cao Y, Wang Z, Zhang Q, et al.. Isolation, Identification, and Genetic Phylogenetic Analysis of Two Different Genotypes of Bovine Parainfluenza 3 Virus in China. Viruses. 2022. DOI: https://doi.org/10.3390/v14102221

[14] Liu X, Luongo C, Matsuoka Y, Park H, Santos C, Yang L, et al.. A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters. Proceedings of the National Academy of Sciences of the United States of America. 2021. DOI: https://doi.org/10.1073/pnas.2109744118

[15] Welch M, Krueger KM, Zhang J, Piñeyro P, Magtoto R, Wang C, et al.. Detection of porcine parainfluenza virus type-1 antibody in swine serum using whole-virus ELISA, indirect fluorescence antibody and virus neutralizing assays. BMC Veterinary Research. 2022. DOI: https://doi.org/10.1186/s12917-022-03196-6

[16] Ohsawa K, Yamada A, Takeuchi K, Watanabe Y, Miyata H, Sato H. Genetic characterization of parainfluenza virus 3 derived from guinea pigs.. Journal of Veterinary Medical Science. 1998. DOI: https://doi.org/10.1292/JVMS.60.919

[17] Socha W, Rola J, Bednarek D, Urban-Chmiel R, Żmudziński J. Shedding course of bovine respiratory syncytial virus and bovine parainfluenza 3 virus in calves vaccinated intranasally. Bulletin of the Veterinary Institute in Pulawy. 2013. DOI: https://doi.org/10.2478/BVIP-2013-0083

[18] Zhou Y, Guo T, Zhao H, Hao Y. Epidemiological Investigation and Phylogenetic Analysis of Bovine Respiratory Disease Complex in Northern China. Veterinary Medicine and Science. 2025. DOI: https://doi.org/10.1002/vms3.70608

[19] Padalino B, Cirone F, Zappaterra M, Tullio D, Ficco G, Giustino A, et al.. Factors Affecting the Development of Bovine Respiratory Disease: A Cross-Sectional Study in Beef Steers Shipped From France to Italy. Frontiers in Veterinary Science. 2021. DOI: https://doi.org/10.3389/fvets.2021.627894

[20] Oliveira TESd, Scuisato GS, Fritzen J, Silva DC, Massi R, Pelaquim IF, et al.. Infectious Disease Agents Associated with Pulmonary Alterations in Aborted Bovine Fetuses. Animals. 2022. DOI: https://doi.org/10.3390/ani12131596

[21] Muftuoglu B, Kuruçay H, Elhag AE, Yildirim S, Cicek-Yildiz Y, Tamer C, et al.. A serosurvey for bovine respirovirus 3 in Turkish domestic ruminants: The first comparison study of A and C genotypes. Veterinary Medicine and Science. 2021. DOI: https://doi.org/10.1002/vms3.534

[22] Hägglund S, Svensson CI, Emanuelson U, Valarcher J, Alenius S. Dynamics of virus infections involved in the bovine respiratory disease complex in Swedish dairy herds. The Veterinary Journal. 2005. DOI: https://doi.org/10.1016/j.tvjl.2005.04.029

[23] Smirnova E, Ivannikova R, Kuzmin V, Lunegov A. Research on the development of vaccines against paragrippe-3 in cattle. Legal regulation in veterinary medicine. 2026. DOI: https://doi.org/10.52419/issn2782-6252.2026.1.93

[24] Yoshitani GD, Camilo S, Fritzen J, Oliveira MV, Lorenzetti E, Lisbôa J, et al.. Serological Profile for Major Respiratory Viruses in Unvaccinated Cows from High-Yielding Dairy Herds. Animals. 2024. DOI: https://doi.org/10.3390/ani14091256

[25] Saeed IK, Ali Y, Abdellatif MM, Mustafa A, Abdel-Mageed AM. Coinfection of some respiratory viruses in cattle: An abattoir study. Onderstepoort Journal of Veterinary Research. 2024. DOI: https://doi.org/10.4102/ojvr.v91i1.2193

[26] H H, S N, E N, Kivelä T, S.-L., Soveri AP, et al.. Viral and Bacterial Pathogens in Bovine Respiratory Disease in Finland. Acta Veterinaria Scandinavica. 2004. DOI: https://doi.org/10.1186/1751-0147-45-193

[27] Yeşilbağ K, Güngör B. Seroprevalence of bovine respiratory viruses in North-Western Turkey. Tropical Animal Health and Production. 2007. DOI: https://doi.org/10.1007/s11250-007-9053-x

[28] Autio T, Pohjanvirta T, Holopainen R, Rikula U, Pentikäinen J, Huovilainen A, et al.. Etiology of respiratory disease in non-vaccinated, non-medicated calves in rearing herds. Veterinary Microbiology. 2006. DOI: https://doi.org/10.1016/j.vetmic.2006.10.001

[29] Gulliksen S, Jor E, Lie KI, Løken T, Åkerstedt J, Østerås O. Respiratory infections in Norwegian dairy calves. Journal of Dairy Science. 2009. DOI: https://doi.org/10.3168/jds.2009-2224

[30] Harms NJ, Jung T, Andrew CL, Surujballi O, Vanderkop M, Savić M, et al.. HEALTH STATUS OF REINTRODUCED WOOD BISON (BISON BISON ATHABASCAE): ASSESSING THE CONSERVATION VALUE OF AN ISOLATED POPULATION IN NORTHWESTERN CANADA. Journal of Wildlife Diseases. 2019. DOI: https://doi.org/10.7589/2017-09-235

[31] Pan W, Xia Y, Wang H, He H. Epidermal growth factor receptor (EGFR) promotes uptake of bovine parainfluenza virus type 3 into MDBK cells.. Veterinary Microbiology. 2022. DOI: https://doi.org/10.1016/j.vetmic.2022.109488

[32] Sun M, Hao F, Li W, Cheng Z, Zhang W, Yang L, et al.. Temporal Dynamics of the Ruminant Type I IFN-Induced Antiviral State against Homologous Parainfluenza Virus 3 Challenge In Vitro. Viruses. 2022. DOI: https://doi.org/10.3390/v14051025

[33] Li W, Li J, Sun M, Yang L, Mao L, Hao F, et al.. Viperin protein inhibits the replication of caprine parainfluenza virus 3 (CPIV 3) by interaction with viral N protein.. Antiviral Research. 2020. DOI: https://doi.org/10.1016/j.antiviral.2020.104903

[34] Kamdi B, Singh R, Singh V, Singh S, Kumar P, Singh KP, et al.. Immunofluorescence and molecular diagnosis of bovine respiratory syncytial virus and bovine parainfluenza virus in the naturally infected young cattle and buffaloes from India. Microbial Pathogenesis. 2020. DOI: https://doi.org/10.1016/j.micpath.2020.104165

[35] Oliveira TE, Scuisato GS, Pelaquim IF, Cunha C, Cunha LS, Flores E, et al.. The Participation of a Malignant Catarrhal Fever Virus and Mycoplasma bovis in the Development of Single and Mixed Infections in Beef and Dairy Cattle With Bovine Respiratory Disease. Frontiers in Veterinary Science. 2021. DOI: https://doi.org/10.3389/fvets.2021.691448

[36] Zhang M, Hill J, Alexander T, Huang Y. The nasal viromes of cattle on arrival at western Canadian feedlots and their relationship to development of bovine respiratory disease.. Transboundary and Emerging Diseases. 2020. DOI: https://doi.org/10.1111/tbed.13873

[37] Saegerman C, Gaudino M, Savard C, Broes A, Ariel O, Meyer G, et al.. Influenza D virus in respiratory disease in Canadian, province of Québec, cattle: relative importance and evidence of new reassortment between different clades.. Transboundary and Emerging Diseases. 2021. DOI: https://doi.org/10.1111/tbed.14085

[38] Diab S, Álvarez I, Ramirez-Barrios R, Reddy AC, Carvallo F. A review of infectious interstitial and bronchointerstitial pneumonia in cattle with an algorithm for the detection of infectious and non-infectious causes.. Journal of Veterinary Diagnostic Investigation. 2026. DOI: https://doi.org/10.1177/10406387251415448

[39] Goldsmith D, Waine K, Legge C, Zachar E, Morrison B, Araya MB, et al.. Interstitial pneumonia and lymphocytic bronchiolitis with interstitial emphysema of unknown cause in Western Canadian fetal and neonatal beef calves. Journal of Veterinary Diagnostic Investigation. 2026. DOI: https://doi.org/10.1177/10406387251410557

[40] Nikunen S, Härtel H, Orro T, Neuvonen E, Tanskanen R, Kivelä S, et al.. Association of bovine respiratory disease with clinical status and acute phase proteins in calves. Comparative Immunology, Microbiology & Infectious Diseases. 2007. DOI: https://doi.org/10.1016/j.cimid.2006.11.004

[41] Thonur L, Maley M, Gilray J, Crook TC, Laming E, Turnbull D, et al.. One-step multiplex real time RT-PCR for the detection of bovine respiratory syncytial virus, bovine herpesvirus 1 and bovine parainfluenza virus 3. BMC Veterinary Research. 2012. DOI: https://doi.org/10.1186/1746-6148-8-37

[42] Nišavić J, Milić N, Radalj A, Stanojković A, Veljović L. Laboratory diagnostics of bovine parainfluenza-3 virus, bovine herpesvirus 1, and bovine respiratory syncytial virus associated with bovine respiratory disease. Biotehnologija u stocarstvu. 2021. DOI: https://doi.org/10.2298/BAH2101001N

[43] Ma Y, Wang X, Chen R, Dong K, Yu X, Li N, et al.. Developing a recombinase-aided amplification method combined with a lateral flow dipstick assay for rapid triplex detection of bovine coronavirus, infectious bovine rhinotracheitis virus, and bovine viral diarrhea virus. Microbiology spectrum. 2025. DOI: https://doi.org/10.1128/spectrum.01628-25

[44] Kishimoto M, Tsuchiaka S, Rahpaya SS, Hasebe A, Otsu K, Sugimura S, et al.. Development of a one-run real-time PCR detection system for pathogens associated with bovine respiratory disease complex. Journal of Veterinary Medical Science. 2017. DOI: https://doi.org/10.1292/jvms.16-0489

[45] Otto C, Angle TC, Passler T, Waggoner P, Fischer T, Rogers B, et al.. Real-Time Detection of a Virus Using Detection Dogs. Frontiers in Veterinary Science. 2016. DOI: https://doi.org/10.3389/fvets.2015.00079

[46] El-Sheikh ME, El-Mekawy MF, Eisa MI, Abouzeid NZ, Abdelmonim M, Bennour EM, et al.. Effect of two different commercial vaccines against bovine respiratory disease on cell-mediated immunity in Holstein cattle. Open Veterinary Journal. 2024. DOI: https://doi.org/10.5455/OVJ.2024.v14.i8.20